CDMRP Pancreatic Cancer Research Program Translational Research Partnership Award

The FY24 PCARP Translational Research Partnership Award supports partnerships (3-5 partners) between clinicians and research scientists. Multi-institutional and convergence science partnerships are strongly encouraged. At least one partner must have expertise either in pancreatic cancer research or pancreatic cancer patient care.

• Early detection research for pancreatic cancer, including the prevalence in individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities.
• Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during diagnosis, treatment, and survivorship.
• Barriers to the implementation of health care, including ways to overcome socioeconomic, geographic, or ethnic and racial disparities.
• Identification and characterization of pancreatic cancer risk including genetic and environmental risk factors, such as diet, obesity, and microbiome.
• Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia.
• Understanding tumor development and progression, from precursors to metastasis
• Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response.
• Biomarkers to predict therapeutic response and guide management strategies
• New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance

It is expected that four (4) awards will be granted. 

Funding: $750,000 total

Duration: 3 years 

Research Authority due date: 20.6.24

Pre application (required) due date: 28.6.24

Full proposal due date: 3.10.24